Results 51 to 60 of about 1,652 (181)

Patient‐Derived Organoids in Functional Precision Oncology: Tumor Modeling, Drug‐Response Prediction, and Clinical Translation

Cell Biochemistry and Function, Volume 44, Issue 10, October 2026.
ABSTRACT Patient‐derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long‐standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three‐dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural, genomic, and phenotypic
Abdullah Jabri, Mohamed Alsharif, Abdulaziz Mhannayeh, Bader Taftafa, Dania Sibai, Abdulrahman Elsalti, Raghad Alsharif, Tanveer Ahmad Mir, Mohammed Imran Khan, Jahan Salma, Ahmed Yaqinuddin   +10 more
wiley   +1 more source

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

Cancer Cell International, 2023
Background Outcomes for patients with relapsed acute lymphoblastic leukemia (ALL) are poor and there is a need for novel therapies to improve outcomes.
Hayden L. Bell, Helen J. Blair, Mankaran Singh, Anthony V. Moorman, Olaf Heidenreich, Frederik W. van Delft, John Lunec, Julie A. E. Irving   +7 more
doaj   +1 more source

Deubiquitinase USP38 Stabilizes PLK1 Expression to Boost DNA Damage Repair in Ovarian Cancer

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 10, October 2026.
ABSTRACT Ovarian cancer (OC) is one of the most prevalent and severe gynecological malignant tumors. DNA damage repair (DDR) is essential in maintaining genome stability. This study aims to investigate the effects and mechanisms of USP38 and PLK1 on DNA damage repair and malignant behavior in OC cells.
Yuan Ma, Ying Li, Kai‐Li Li
wiley   +1 more source

AZD1775 Induces Toxicity Through Double-Stranded DNA Breaks Independently of Chemotherapeutic Agents in p53-Mutated Colorectal Cancer Cells [PDF]

, 2017
AZD1775 is a small molecule WEE1 inhibitor used in combination with DNA-damaging agents to cause premature mitosis and cell death in p53-mutated cancer cells.
Anna Tiffany Littlejohns, Webster, PJ, Peter John Webster, Burke, DA, Littlejohns, AT, Gaunt, HJ, Prasad, KR, Hannah Jane Gaunt, Dermot Anthony Burke, K. Raj Prasad, David John Beech, Beech, DJ   +11 more
core   +1 more source

Supplementary Figure Legends from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

, 2023
<p>Supplementary Figure Legends</p>
Patricia M. LoRusso, Michael E. Berens, Lance K. Heilbrun, Harshil D. Dhruv, Shwetal Mehta, Alanna Derogatis, Seongho Kim, Jianmei Wu, Karri Stark, Julie Boerner, Jing Li, Nader Sanai   +11 more
openaire   +1 more source

Figure S5 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia

, 2017
Cell cycle analysis of acute leukemia cells treated with olaparib and AZD1775. A. The indicated cell lines were treated with DMSO (vehicle), olaparib (2 uM), and/or AZD1775 (200 nM) for 48 hr then fixed and stained with propidium iodide.
Tamara B. Garcia (8533719), Lori Gardner (14935568), Craig T. Jordan (210141), Chengjing Zhou (3907645), Sujatha Venkataraman (194808), Susan P. Fosmire (14919194), Dmitry Baturin (390190), Rajeev Vibhakar (247074), Christopher C. Porter (8533728), Jonathan C. Snedeker (15074359)   +9 more
core   +1 more source

Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model

Cancer Cell International, 2020
Background CDK4/6 inhibitors such as ribociclib are becoming widely used targeted therapies in hormone-receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) breast cancer. However, cancers can advance due to drug resistance, a
Vince Kornél Grolmusz, Jinfeng Chen, Rena Emond, Patrick A. Cosgrove, Lance Pflieger, Aritro Nath, Philip J. Moos, Andrea H. Bild   +7 more
doaj   +1 more source

Interferon‐Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple‐Negative Breast Cancer

Advanced Science, Volume 13, Issue 6, 30 January 2026.
Triple‐negative breast cancer exhibits variable sensitivity to PRMT5 inhibition. Basal interferon signaling is identified as a key biomarker of response. PARP inhibition with olaparib induces IFN signaling, sensitizing resistant TNBC cells to PRMT5 inhibitors.
Ziwen Zhang, Sheyu Zhang, Lu Guo, Yichun Pan, Juan Huang, Yishuai Ji, Jiaqi Tao, Yong Wei, Xiaojia Wang, Qin Wu   +9 more
wiley   +1 more source

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Application of synthetic lethality screening in drug resistance models. Abstract Background and Rationale Synthetic lethality (SL)‐based strategies hold significant promise for overcoming therapeutic resistance, a critical bottleneck in cancer treatment where cancer cells evade anticancer therapies, leading to diminished efficacy or treatment failure ...
Junyan Li, Liyuan Zhang, Yan Shang, Juan Liu, Hailong Zhao   +4 more
wiley   +1 more source

Drosophila Cancer Models Identify Functional Differences between Ret Fusions

Cell Reports, 2016
We generated and compared Drosophila models of RET fusions CCDC6-RET and NCOA4-RET. Both RET fusions directed cells to migrate, delaminate, and undergo EMT, and both resulted in lethality when broadly expressed.
Sarah Levinson, Ross L. Cagan
doaj   +1 more source